Predicting how bladder cancer responds to BCG
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were diagnosed with bladder cancer (Ta, carcinoma in situ, or T1) within the last 90 days
- You have had visible bladder tumor removed (or a cystoscopy shows none visible) within 30 days of starting BCG
- You have intermediate- or high-grade bladder cancer, and not a specific type like pure squamous or adenocarcinoma
- No signs of spread: imaging within 90 days shows no lymph node or metastatic spread, and tests show no kidney/ureter cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This study is testing a way for people with early-stage bladder cancer to receive their BCG treatment at home, with extra support. It aims to see if doing treatment at home is safe and helpful for patients.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.